Alison B Fleming
Overview
Explore the profile of Alison B Fleming including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
221
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fleming A, Mayock S, Saim S
Clin Drug Investig
. 2018 Jun;
38(8):799-800.
PMID: 29949104
No abstract available.
2.
Brennan M, Kopecky E, Marseilles A, OConnor M, Fleming A
Pain Manag
. 2017 Nov;
7(6):461-472.
PMID: 29171358
Aim: To further characterize the pharmacokinetics of Xtampza ER. Subjects & Methods: This was an open-label, randomized, active-controlled, five-treatment, five-period, naltrexone-blocked, cross-over study. Healthy subjects received five equivalent oxycodone doses:...
3.
Mayock S, Saim S, Fleming A
Clin Drug Investig
. 2017 Nov;
37(12):1203.
PMID: 29094281
Following correction should be noted.
4.
Butler S, Black R, Fleming A
Pain Med
. 2017 Oct;
19(8):1613-1627.
PMID: 29016905
Objective: Some crush-resistant tablet formulations (CRTs) reduce prescription opioid abuse by nonoral routes of administration (ROAs), especially insufflation and injection, while oral abuse increases. Oral abuse involving product manipulation vs...
5.
Mayock S, Saim S, Fleming A
Clin Drug Investig
. 2017 Sep;
37(12):1117-1124.
PMID: 28940174
Background And Objective: Extended-release (ER) opioids are associated with high rates of abuse. Recreational opioid users often manipulate ER formulations to achieve a high plasma concentration in a short amount...
6.
Gudin J, Kopecky E, Fleming A
Pain Med
. 2017 Jan;
18(5):992-994.
PMID: 28074029
No abstract available.
7.
Kopecky E, Fleming A, Levy-Cooperman N, OConnor M, Sellers E
J Clin Pharmacol
. 2016 Sep;
57(4):500-512.
PMID: 27669664
Oxycodone DETERx (Collegium Pharmaceutical Inc, Canton, Massachusetts) is an extended-release, microsphere-in-capsule, abuse-deterrent formulation designed to retain its extended-release properties after tampering (eg, chewing/crushing). This randomized, double-blind, placebo-controlled, triple-dummy study evaluated...
8.
McCarberg B, Kopecky E, OConnor M, Marseilles A, Varanasi R, Thompson C, et al.
Curr Med Res Opin
. 2016 Sep;
32(12):1975-1982.
PMID: 27668546
Background: Patients with chronic pain may experience difficulty swallowing, in part due to worsening disease, comorbid conditions, iatrogenic etiology, or age. Patients or caregivers may manipulate extended-release (ER) opioid formulations...
9.
Fleming A, Scungio T, Grima M, Mayock S
J Opioid Manag
. 2016 Feb;
12(1):57-65.
PMID: 26908304
Objective: Abuse of prescription analgesics is a well-recognized problem, with nearly 2 million people aged 12 years or older initiating nonmedical use of pain relievers in 2012. The prevalence of...
10.
Webster L, Kopecky E, Smith M, Fleming A
Pain Med
. 2016 Jan;
17(6):1112-30.
PMID: 26814256
Objective: Evaluate the human abuse potential (HAP) of an experimental, microsphere-in-capsule formulation of extended-release oxycodone (oxycodone DETERx®) (herein "DETERx"). Design: Randomized, double-blind, double-dummy, positive- and placebo-controlled, single-dose, four-phase, four-treatment, crossover...